This website is intended for U.S. Healthcare Professionals only.

Contact Roche  

Clinical impact

See how the Elecsys® Phospho-Tau (181P) CSF and β-Amyloid (1-42) CSF II assays compare to amyloid PET scan

Amyloid pathology detection1

A negative result, defined as pTau181/Abeta42 ratio value below cutoff or an Abeta42 value above the measuring range, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive result, defined as pTau181/Abeta42 ratio value above cut-off, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder. The pTau181/Abeta42 ratio result is used as an adjunct to other clinical diagnostic evaluations.1

Elecsys® AD CSF ratio achieves 90% concordance with amyloid PET1,2

As depicted in the PET read classification graph, a pTau181/Abeta42 ratio result above the cutoff is consistent with a positive amyloid PET visual read.2

Elecsys® pTau181/Abeta42 ratio outperforms Abeta 42 as a standalone marker and achieves an area under the curve (AUC) of 96.3% (95.2%-98.0%) compared to single marker Abeta 92.1% (90.0%-94.3%) AUC.2

Abeta42, β-Amyloid (1-42); pTau181, Phospho-Tau (181P)

Stay Connected

Sign-up to receive updates related to Roche Diagnostics and the Elecsys® AD CSF assays

1. Elecsys® Method Sheet: ms_08821941501, ms_08846715501
2. Hansson O, et al. Alzheimers Dement. 2018;14(11):1470-1481.